WeTrials
Recruiting

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer

What is this study?

This study is testing a new way to give a targeted cancer medication called amivantamab as a shot under the skin, either alone or with other cancer treatments. Researchers want to see how well these combinations fight advanced lung cancer and check if they are safe for patients.

Who can participate?

You might be able to join if you have advanced non-small cell lung cancer with specific gene mutations and are generally in good physical shape. Your doctors will also check your organ function and treatment history to make sure the study is a good fit for you.

What will happen?

Participants will receive the study medications—which may include targeted therapies and standard chemotherapy—according to a specific schedule. You will also have regular check-ups and scans to monitor your health and how your tumor responds to the treatment.

Where and when?

This study is currently recruiting patients at various medical centers in California, United States. Your care team can help you find the closest participating location.

Key Points
  • 1Tests a convenient under-the-skin shot for an advanced lung cancer treatment.
  • 2Combines the study drug with other targeted therapies or standard chemotherapy.
  • 3Currently recruiting patients at multiple medical locations in California.

Related video

PALOMA-2: subcutaneous amivantamab plus lazertinib update (2026)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Carcinoma, Non-small-Cell Lung

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.